Veracyte Inc
Ownership
Ownership Structure
Who owns Veracyte Inc (VCYT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.4% of the shares are freely tradable; institutional investors hold 113.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 16.78 | 13,486,437 | +2.4 | 06/30/2026 |
| FMR Inc | 9.58 | 7,702,746 | -0.8 | 06/30/2026 |
| Artisan Partners Limited Partnership | 6.89 | 5,538,404 | +0.8 | 06/30/2026 |
| Vanguard Portfolio Management, LLC | 5.87 | 4,716,191 | +6.1 | 06/30/2026 |
| State Street Corp | 5.84 | 4,698,128 | -6.8 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.47 | 3,593,922 | +1.7 | 06/30/2026 |
| Dimensional Fund Advisors, Inc. | 3.52 | 2,826,524 | -1.9 | 06/30/2026 |
| First Trust Advisors L.P. | 3.12 | 2,507,902 | +18.5 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 5.95 | 4,787,107 | +0.0 | 09/30/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.17 | 2,546,188 | +0.3 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Stapley Marc | Chief Executive Officer | 432,073 | 22,683,833 $ | Sep 2, 2026 | direct |
| Chambers Rebecca | Chief Financial Officer | 166,025 | 8,716,313 $ | Sep 4, 2026 | direct |
| Febbo Phillip G. | Chief Scientific & Med Officer | 133,048 | 6,985,020 $ | Sep 4, 2026 | direct |
| McGuire Annie | EVP, General Counsel | 131,160 | 6,885,900 $ | Sep 4, 2026 | direct |
| Leite John | Global Chief Commercial Off | 124,329 | 6,527,273 $ | Sep 21, 2026 | direct |
| Wygant Jonathan | VP, Chief Accounting Officer | 41,920 | 2,200,800 $ | Oct 28, 2026 | direct |
| Bhanji Muna | Director | 40,854 | 2,144,835 $ | Oct 19, 2026 | direct |
| Holstein Jens | Director | 27,471 | 1,442,228 $ | Oct 27, 2026 | direct |
| Eastham Karin | Director | 10,247 | 537,968 $ | Oct 27, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 28, 2026 | Wygant Jonathan | VP, Chief Accounting Officer | Other | 1,306 | 50.31 | 65,705 |
| Oct 27, 2026 | Holstein Jens | Director | Sell | 7,500 | 50.00 | 375,000 |
| Oct 27, 2026 | Holstein Jens | Director | Other | 7,500 | 35.30 | 264,750 |
| Oct 27, 2026 | Eastham Karin | Director | Sell | 14,850 | 50.00 | 742,573 |
| Oct 27, 2026 | Eastham Karin | Director | Other | 10,000 | 27.01 | 270,100 |
| Oct 19, 2026 | Bhanji Muna | Director | Sell | 1,864 | 43.70 | 81,457 |
| Sep 24, 2026 | Holstein Jens | Director | Sell | 7,500 | 47.00 | 352,500 |
| Sep 24, 2026 | Holstein Jens | Director | Other | 7,500 | 35.30 | 264,750 |
| Sep 21, 2026 | Leite John | Global Chief Commercial Off | Sell | 4,015 | 40.00 | 160,600 |
| Sep 14, 2026 | Holstein Jens | Director | Sell | 5,000 | 40.95 | 204,747 |
| Sep 4, 2026 | McGuire Annie | EVP, General Counsel | Sell | 1,100 | 43.67 | 48,039 |
| Sep 4, 2026 | McGuire Annie | EVP, General Counsel | Sell | 2,154 | 42.79 | 92,173 |
| Sep 4, 2026 | Chambers Rebecca | Chief Financial Officer | Sell | 1,175 | 43.71 | 51,364 |
| Sep 4, 2026 | Chambers Rebecca | Chief Financial Officer | Sell | 2,477 | 42.81 | 106,030 |
| Sep 4, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,705 | 43.66 | 118,105 |
| Sep 4, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 10,405 | 42.89 | 446,305 |
| Sep 2, 2026 | Leite John | Global Chief Commercial Off | Other | 3,961 | 44.88 | 177,770 |
| Sep 2, 2026 | McGuire Annie | EVP, General Counsel | Other | 3,215 | 44.88 | 144,289 |
| Sep 2, 2026 | Chambers Rebecca | Chief Financial Officer | Other | 3,603 | 44.88 | 161,703 |
| Sep 2, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | Other | 3,639 | 44.88 | 163,318 |
| Sep 2, 2026 | Wygant Jonathan | VP, Chief Accounting Officer | Other | 1,361 | 44.88 | 61,082 |
| Sep 2, 2026 | Stapley Marc | Chief Executive Officer | Other | 8,782 | 44.88 | 394,136 |
| Sep 1, 2026 | Bhanji Muna | Director | Sell | 1,864 | 42.97 | 80,096 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 4, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.